Table 1.
Immunological analysis of the Patient
| Test | Patient | Control (ranges) |
|---|---|---|
| Lymphocyte counts (/3mm) | ||
| Percentage | 13 | 14-44 |
| Absolute counts | 468 | 900-3000 |
| Serum Immunoglobulins (mg/dl) | ||
| IgG | 1,100 | 694-1,618 |
| IgA | 175 | 68-378 |
| IgM | 26 | 65-263 |
| IgE (IU/ml) | 7 | 10-150 |
| Lymphocyte subsets % (#)** | ||
| CD3+ | 9 (42) | 62-84 (619-1847) |
| CD3+CD4+ | 2 (9) | 31-61 (338-1194) |
| CD3+CD8+ | 4 (19) | 10-38 (85-729) |
| CD4/CD8 ratio | 0.47 | 0.9-3.7 |
| CD19+ | 51 (239) | 5-26 (51-473) |
| CD3-CD56+CD16+ | 38 (178) | 1-7 (12-349) |
| Delayed Type skin Hypersensitivity | ||
| Mumps | Negative | Positive |
| Tetanus | Negative | Positive |
| PPD | Negative | Positive* |
| Lymphocyte proliferation (counts per min) | ||
| PHA | 4,509 | 153,754-279,243 |
| ConA | 1,128 | 122,130-382,789 |
| PWM | 14,660 | 147,894-230,054 |
| NK cytotoxicity | ||
| Lytic unit | 4 | 8-40 |
| TB Quantiferon (IU/ml) | 0.01 | > 0.35 |
*
In subjects exposed to Mycobacterium or BCG vaccinated;
**
Lymphocyte subsets were performed at least on 4 separate occasions over 2 years period and were similar.